Lipid nanoparticles are enabling a new generation of engineered cell therapies with a push toward more complex cell engineering and gene editing for allogeneic therapies.
Gene delivery platforms need to support a diversity of genetic engineering strategies for the development of genomic medicines. Read more about how lipid nanoparticles can accelerate development from discovery to scale-up.
Read this article to learn more about the key stages of drug discovery and screening, and how to overcome key bottlenecks in screening mRNA-LNPs to rapidly develop genomic medicines.
Speed to market is critical but the path to developing a commercial mRNA-lipid nanoparticle (LNP) drug product is complex with challenges at every stage. Learn why single-use technology is gaining attention for its ability to facilitate a reliable and robust manufacturing process for biopharma manufacturers looking to scale up mRNA therapeutics.
This website uses cookies to ensure you get the best experience on our website. Learn more
